EWTX
Edgewise Therapeutics, Inc.Healthcare·Biotechnology
$34.16
$3.7B market cap
Revenue
$0.0M
Free Cash Flow
$-81.2M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to addres
2-Year Price History
$32.70+90.9%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -53.5 | -54.1 | -49.0 | -42.5 | -42.8 | -0.3 | 499.6 | 3.8 | 107.1 | -152.6% | -- | -- |
| Act | 2025-Q4 | 0.0 | -51.9 | -56.0 | -50.2 | -38.6 | -38.4 | -0.2 | 530.1 | 4.0 | 102.9 | -128.9% | -- | -- |
Valuation & Metrics
Market Stats
Price$34.16
Market Cap$3.7B
Enterprise Value$3.2B
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-2.2%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-99.2M
Free Cash Flow$-81.2M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-140.8%
WC Change % Rev0.0%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares10.1M
Days to Cover9.3
Change (vs Prior)+0.6%
Need at least 2 settlement dates for chart
Employees
Headcount117
Revenue / Employee$0
Gross Profit / Employee$-5,043
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
90.7%(+34.5% YoY)
196 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
15.0%(+5.3% YoY)
11 filers
Vanguard, iShares, SPDR
Market makers
0.1%(-0.1% YoY)
5 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | $489M | $13.13 | +$0 | +$15.6M | -8.6% | $4.38B |
| RA CAPITAL MANAGEMENT, L.P. | $328M | $17.45 | +$0 | +$47.9M | -4.6% | $9.44B |
| Paradigm Biocapital Advisors LP | $232M | $21.23 | +$26.0M | +$93.6M | +2.0% | $4.69B |
| BAKER BROS. ADVISORS LP | $207M | $14.54 | +$0 | +$13.2M | -0.5% | $16.13B |
| BlackRock, Inc.Passive | $204M | $26.04 | −$5.0M | −$379K | -0.2% | $5.69T |
| JANUS HENDERSON GROUP PLC | $186M | $22.66 | +$42.5M | +$19.9M | +1.2% | $209.29B |
| Novo Holdings A/S | $169M | $15.70 | +$0 | +$0 | -3.8% | $1.23B |
| DRIEHAUS CAPITAL MANAGEMENT LLC | $141M | $21.34 | +$9.0M | +$97.7M | +0.3% | $13.60B |
| Siren, L.L.C. | $140M | $19.34 | −$3.1M | +$86.1M | +6.1% | $3.61B |
| PERCEPTIVE ADVISORS LLC | $139M | $21.09 | −$1.1M | −$66.9M | -1.3% | $5.05B |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $119M | $31.50 | +$119M | +$119M | — | $4.04T |
| Cormorant Asset Management, LLC | $103M | $21.31 | −$788K | −$26.5M | -2.6% | $1.95B |
| BRAIDWELL LP | $73.9M | $19.40 | −$90.2M | −$3.5M | -1.9% | $2.63B |
| MORGAN STANLEY | $70.7M | $21.71 | −$20.9M | +$57.9M | -0.3% | $1.65T |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $56.4M | $14.98 | +$1.4M | +$4.2M | +2.3% | $1.61T |
| STATE STREET CORPPassive | $54.1M | $15.55 | −$16K | −$28K | -0.2% | $2.89T |
| MPM BioImpact LLC | $52.3M | $14.72 | +$171K | +$17.5M | -1.9% | $1.29B |
| Integral Health Asset Management, LLC | $50.4M | $20.60 | +$3.1M | +$29.1M | -0.5% | $1.64B |
| Bellevue Group AG | $48.1M | $15.63 | +$0 | +$3.1M | -4.3% | $4.20B |
| Soleus Capital Management, L.P. | $45.7M | $27.33 | +$17.0M | +$43.4M | -0.9% | $2.47B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BULLISH
Holders
-1.73%
avg per quarter
Holders (ex-self)
-1.87%
excl. this stock
Buyers (this Q)
+0.50%
95 buyers · $0.55B in
Sellers (this Q)
-23.93%
78 sellers · $-0.04B out
alpha coverage: 96% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
+8.0%
how holders react when this stock falls
On quiet Qs
+24.7%
−10% to +10% baseline
On rallies (+10%+)
-8.4%
how they react when this stock rises
Holders' portfolio flow this Q
-0.3%
outflows — trims may be forced
Sellers' portfolio flow this Q
-4.3%
Sellers shed AUM broadly — partly forced.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-2.4%
Holder mid (any stock)
-2.8%
Holder rally (any stock)
-3.0%
Biggest decreases this quarter
BRAIDWELL LP−$90.2Mα-1.9UBS Group AG−$25.4Mα-0.3MORGAN STANLEY−$20.9Mα-0.3DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)exited−$19.0MEversept Partners, LPexited−$8.4MBlackRock, Inc.−$5.0Mα-0.2BANK OF AMERICA CORP /DE/−$4.6Mα-0.1BALYASNY ASSET MANAGEMENT LLCexited−$3.8MSiren, L.L.C.−$3.1Mα+6.1Exome Asset Management LLCexited−$2.5M
New buyers this quarter
Top-5 holders · 39.2%
ORBIMED ADVISORS LLC--
RA CAPITAL MANAGEMENT, L.P.--
Paradigm Biocapital Advisors LP--
BAKER BROS. ADVISORS LP--
BlackRock, Inc.--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
ORBIMED ADVISORS LLC15.5MRA CAPITAL MANAGEMENT, L.P.10.4MParadigm Biocapital Advisors LP7.4MBAKER BROS. ADVISORS LP6.6MJANUS HENDERSON GROUP PLC5.9MNovo Holdings A/S5.3MPERCEPTIVE ADVISORS LLC4.4MDRIEHAUS CAPITAL MANAGEMENT LLC4.5MSiren, L.L.C.4.4MBRAIDWELL LP2.3M
Related Stocks
Investors who own this also own
Stocks held by the same active managers as this one, ranked by score — how much more often these appear together than random chance (1× = baseline). Excludes index ETFs and market makers; minimum 3 shared holders.
| Ticker | Name | Co-holders | Score |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | 6 | 119.47× |
| MBX | MBX Biosciences, Inc. Common Stock | 4 | 98.03× |
| CRNX | Crinetics Pharmaceuticals, Inc. | 4 | 98.03× |
| OLMA | Olema Pharmaceuticals, Inc. | 3 | 95.58× |
| XENE | Xenon Pharmaceuticals Inc. | 6 | 91.03× |
| IRON | Disc Medicine, Inc. | 5 | 88.50× |
| NUVL | Nuvalent, Inc. | 4 | 84.96× |
| TNGX | Tango Therapeutics, Inc. | 4 | 84.96× |
| KOD | Kodiak Sciences Inc. | 3 | 79.65× |
| TVTX | Travere Therapeutics, Inc. | 3 | 79.65× |
| SYRE | Spyre Therapeutics, Inc. | 4 | 74.97× |
| ERAS | Erasca, Inc. | 4 | 70.80× |
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (4 analysts)$42.002300.0%
Last Year (5 analysts)$37.601010.0%
Current Price$34.16
Analyst Ratings
7
1
1
Buy: 7Hold: 1Sell: 1Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$199K
1 txn · 1 insider · 10,700 sh
Sells ($, 12mo)
$11.43M
14 txns · 7 insiders · 455,817 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-05-05 | SELL | Donovan Joanne M. | officer: CMO | 50,000 | $38.57 | $1.93M | $168K |
| 2026-05-04 | SELL | Donovan Joanne M. | officer: CMO | 5,230 | $31.29 | $164K | $137K |
| 2026-04-01 | SELL | Donovan Joanne M. | officer: CMO | 28,662 | $32.31 | $926K | $310K |
| 2026-03-31 | SELL | Donovan Joanne M. | officer: CMO | 21,338 | $32.12 | $685K | $308K |
| 2026-03-27 | SELL | Donovan Joanne M. | officer: CMO | 16,358 | $30.98 | $507K | $297K |
| 2026-01-21 | SELL | Edris Badreddin | director | 115,471 | $29.44 | $3.40M | $584K |
| 2025-11-12 | SELL | Russell Alan J | director, officer: Chief Scientific Officer | 100,000 | $21.12 | $2.11M | $494K |
| 2025-11-11 | BUY | Fox Jonathan C | director | 10,700 | $18.64 | $199K | $442K |
| 2025-08-26 | SELL | Russell Alan J | director, officer: Chief Scientific Officer | 100,000 | $14.60 | $1.46M | $342K |
| 2025-08-12 | SELL | Carruthers R Michael | officer: Chief Financial Officer | 1,428 | $13.39 | $19K | $1.15M |
| 2025-08-12 | SELL | Derakhshan Behrad | officer: Chief Business Officer | 2,491 | $13.39 | $33K | $317K |
| 2025-08-12 | SELL | Donovan Joanne M. | officer: CMO | 2,862 | $13.39 | $38K | $340K |
| 2025-08-12 | SELL | KOCH KEVIN | director, officer: President and CEO | 7,972 | $13.39 | $107K | $410K |
| 2025-08-12 | SELL | MOORE JOHN R | officer: General Counsel | 2,098 | $13.39 | $28K | $137K |
| 2025-08-12 | SELL | Russell Alan J | director, officer: Chief Scientific Officer | 1,907 | $13.39 | $26K | $313K |
Order Flow (FINRA, ~3w lag)
21.4%retail+7.1pp
27.7%dark-2.1pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Edgewise Therapeutics: A High-Burn Clinical Engine Powered by Persistent Shareholder Dilution
Overall Risk
6/10
Fraud
2/10
Dilution
9/10
Insolvency
4/10
Earnings Overstated
2/10
Hidden Liabilities
3/10
Legal
2/10
Audit Warnings
2/10
Hidden Upside
4/10
Contextually Acceptable
8/10